Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation

Journal of Diabetes Investigation

Volumn 1, Issue 5, 2010, Pages 172-183

  Tamaki, Motoyuki ^a   Fujitani, Yoshio ^a,b   Uchida, Toyoyoshi ^a   Hirose, Takahisa ^a,b   Kawamori, Ryuzo ^a,b,c,d   Watada, Hirotaka ^a,d  

^a Metabolism and Endocrinology ^*  (Japan)

^b Center for Therapeutic Innovations in Diabetes   (Japan)

^c Center for Beta Cell Biology and Regeneration   (Japan)

^d JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastrin; GLP 1; Type 2 diabetes

Indexed keywords

EXENDIN 4; GASTRIN; GLUCOSE; INSULIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROGENIN 3; TRANSCRIPTION FACTOR MAFA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DENSITY; CELL DIFFERENTIATION; CELL DIVISION; CELL MATURATION; CELL STIMULATION; CELL STRUCTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN SYNTHESIS; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 79953742572     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00044.x     Document Type: Article

References (48)

1. Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 1999; 42: 499-518.
2. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47: 358-364.
3. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-1992.
4. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
5. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004; 47: 581-589.
6. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotechnol 2005; 23: 857-861.
7. Knauf C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115: 3554-3563.
8. Burcelin R, Da Costa A, Drucker D, et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001; 50: 1720-1728.
9. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
10. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713.
11. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006; 91: 1916-1923.
12. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612-615.
13. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471-478.
14. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002; 45: 1263-1273.
15. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
16. Zhou J, Wang X, Pineyro MA, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon-and insulin-producing cells. Diabetes 1999; 48: 2358-2366.
17. Yew KH, Prasadan KL, Preuett BL, et al. Interplay of glucagon-like peptide-1 and transforming growth factor-beta signaling in insulin-positive differentiation of AR42J cells. Diabetes 2004; 53: 2824-2835.
18. Song SY, Gannon M, Washington MK, et al. Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Gastroenterology 1999; 117: 1416-1426.
19. Krakowski ML, Kritzik MR, Jones EM, et al. Transgenic expression of epidermal growth factor and keratinocyte growth factor in beta-cells results in substantial morphological changes. J Endocrinol 1999; 162: 167-175.
20. Cras-Meneur C, Elghazi L, Czernichow P, et al. Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: a balance between proliferation and differentiation. Diabetes 2001; 50: 1571-1579.
21. Huotari MA, Palgi J, Otonkoski T. Growth factor-mediated proliferation and differentiation of insulin-producing INS-1 and RINm5F cells: identification of betacellulin as a novel beta-cell mitogen. Endocrinology 1998; 139: 1494-1499.
22. Yamamoto K, Miyagawa J, Waguri M, et al. Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes 2000; 49: 2021-2027.
23. Mashima H, Ohnishi H, Wakabayashi K, et al. Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells. J Clin Invest 1996; 97: 1647-1654.
24. Ogihara T, Watada H, Kanno R, et al. p38 MAPK is involved in activin A- and hepatocyte growth factor-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells. J Biol Chem 2003; 278: 21693-21700.
25. Suarez-Pinzon WL, Yan Y, Power R, et al. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 2005; 54: 2596-2601.
26. Rooman I, Bouwens L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia 2004; 47: 259-265.
27. Brand SJ, Tagerud S, Lambert P, et al. Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin. Pharmacol Toxicol 2002; 91: 414-420.
28. Suarez-Pinzon WL, Lakey JR, Brand SJ, et al. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. J Clin Endocrinol Metab 2005; 90: 3401-3409.
29. Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant 2008; 17: 631-640.
30. Buteau J, Foisy S, Joly E, et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003; 52: 124-132.
31. Uchida T, Iwashita N, Ohara-Imaizumi M, et al. Protein kinase Cdelta plays a non-redundant role in insulin secretion in pancreatic beta cells. J Biol Chem 2007; 282: 2707-2716.
32. Shao J, Iwashita N, Ikeda F, et al. Beneficial effects of cande-sartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006; 344: 1224-1233.
33. Xu X, D'Hoker J, Stange G, et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 2008; 132: 197-207.
34. Rooman I, Lardon J, Flamez D, et al. Mitogenic effect of gas-trin and expression of gastrin receptors in duct-like cells of rat pancreas. Gastroenterology 2001; 121: 940-949.
35. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650-19655.
36. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
37. Kim MJ, Kang JH, Park YG, et al. Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element. J Endocrinol 2006; 188: 623-633.
38. Park S, Dong X, Fisher TL, et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 2006; 281: 1159-1168.
39. Zhang YQ, Mashima H, Kojima I. Changes in the expression of transcription factors in pancreatic AR42J cells during differentiation into insulin-producing cells. Diabetes 2001; 50(Suppl 1): S10-S14.
40. Kodama S, Toyonaga T, Kondo T, et al. Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice. Biochem Biophys Res Commun 2005; 327: 1170-1178.
41. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391: 900-904.
42. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117: 246-257.
43. Rooman I, Lardon J, Bouwens L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 2002; 51: 686-690.
44. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61: 687-693.
45. Uchida T, Nakamura T, Hashimoto N, et al. Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat Med 2005; 11: 175-182.
46. Julien S, Laine J, Morisset J. Regulation of rat pancreatic CCKB receptor and somatostatin expression by insulin. Diabetes 2004; 53: 1526-1534.
47. Todisco A, Ramamoorthy S, Witham T, et al. Molecular mechanisms for the antiapoptotic action of gastrin. Am J Physiol Gastrointest Liver Physiol 2001; 280: G298-G307.
48. Wang TC, Bonner-Weir S, Oates PS, et al. Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J Clin Invest 1993; 92: 1349-1356.